March 14th 2024
The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
November 21st 2022
Blood Test Could Identify Patients at Risk of Nonalcoholic Fatty Liver Disease, Study Says
July 23rd 2021The gold standard for diagnosing liver disease is a liver biopsy, but researchers are seeking a simpler way to identify those at risk, given the silent nature of early disease and rising incidence around the globe.
Read More
NAFLD Increases Mortality in Children and Young Adults Over the Long Term
July 8th 2021A long-term Swedish study found that nonalcoholic fatty liver disease (NALFD) significantly increased mortality in children and young adults, particularly due to cancer, cardiometabolic disease, and liver disease.
Read More
Baffled by NAFLD: The Horse Might Be Out of the Barn but Should Not Take Us for a Ride
May 28th 2021As awareness of nonalcoholic fatty liver disease (NAFLD) rises, it is essential to develop and implement a rigorously determined approach to identify patients who will, or will not, benefit from diagnostic evaluation.
Read More
Population-Based Return on Investment of Deploying Transient Elastography
Deploying vibration-controlled transient elastography/controlled attenuation parameter devices at the population level is a financially advantageous solution to address the epidemic of fatty liver disease.
Read More